Study Evaluating the Efficacy and Safety With CD19CAR-T for Relapsed or Refractory Acute Lymphoblastic Leukemia
The clinical trial is focused on evaluating the efficacy and safety of CD19CAR-T therapy for patients with relapsed or refractory acute lymphoblastic leukemia (ALL). Given the high unmet medical need in this patient population, successful outcomes could position the sponsor, Chinese PLA General Hospital, as a key player in the CAR-T therapy market, particularly in the Asia-Pacific region. The competitive landscape includes established CAR-T therapies such as Kymriah (tisagenlecleucel) and Breyanzi (lisocabtagene maraleucel), which may pose challenges in terms of market entry and pricing strategies. Diligence should focus on the trial's recruitment progress, potential partnerships, and regulatory pathways in China and beyond.
Indication: Relapsed Acute Lymphoblastic Leukemia
Modality: combination therapy
Target: CD19 positive cells
Sponsor: Chinese PLA General Hospital
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 15, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: CD19 positive cells
View original source fields
Condition raw: Relapsed Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia
Condition normalized: Relapsed Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia
Modality raw: combination therapy
Modality normalized: combination therapy
Target raw: CD19 positive cells
Target normalized: CD19 positive cells